Safety of ?2-Agonists in Asthma: Linking Mechanisms, Meta-Analyses and Regulatory Practice.

ABSTRACT: An epidemic of asthma fatalities in the 1970s prompted a series of case-control studies which indicated that short acting ?-agonists increased the risk of death. Subsequent mechanistic and pharmacodynamic studies have suggested that ?-agonist monotherapy facilitates airway inflammation, although when co-administered with inhaled corticosteroids (ICSs), similar evidence is lacking. The Salmeterol Multicenter Asthma Research Trial, which revealed a fourfold increase in asthma-related deaths in salmeterol-treated patients, prompted a paradigm shift in the evidential assessment of ?-agonist safety. The FDA's meta-analysis of over 60,000 patients ultimately concluded that long-acting ?-agonist (LABA) therapy increased the risk of serious asthma-related events. However, this meta-analysis itself raised questions given a large body of omitted data and a limited emphasis on the risk of ICS-LABA co-administration. Subsequently, the FDA mandated the conduct of five large studies to definitively ascertain whether ICS-LABAs increase asthma-related risk. Whether this ambitious programme will provide certainty remains to be seen given issues of multiplicity, the very low frequency of fatal and near-fatal asthma, and the administration of a free combination of ICS and LABA in one trial. The FDA's de facto use of FEV1 as a safety parameter, based on findings from the Foradil NDA, is a further topical issue: subsequent clinical study data, considerations relating to regional pulmonary drug deposition and pharmacological differences between different ?-agonists suggest that FEV1 may be a suboptimal safety metric. Models evaluating airway inflammation and bronchial reactivity may be more appropriate to assess the relative risk of asthma-related events.

SUBMITTER: Dissanayake SB 

PROVIDER: S-EPMC4406964 | biostudies-other | 2015 May

REPOSITORIES: biostudies-other